{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:15:27Z","timestamp":1756383327375},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00393-014-1459-z","type":"journal-article","created":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T06:35:49Z","timestamp":1428474949000},"page":"191-198","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antiphospholipid-Syndrom"],"prefix":"10.1007","volume":"74","author":[{"given":"C.","family":"Specker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,9]]},"reference":[{"key":"1459_CR1","unstructured":"Feinstein DJ, Rapaport SJ (1972) Acquired inhibitors of blood coagulation. In: Spaet TN (ed) Progress in hemostasis and thrombosis, 1st edn. Grune & Stratton, New York, pp\u00a075\u201395"},{"key":"1459_CR2","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1001\/archinte.1986.00360230069012","volume":"146","author":"Harris","year":"1986","unstructured":"Harris EN, Chan JKH, Asherson RA et al (1986) Thrombosis, recurrent fetal loss and thrombocytopenia. Arch Intern Med 146:2153\u20132156","journal-title":"Arch Intern Med"},{"key":"1459_CR3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0140-6736(93)91477-4","volume":"342","author":"Hughes","year":"1993","unstructured":"Hughes GRV (1993) The antiphospholipid syndrome: ten years on. Lancet 342:341\u2013344","journal-title":"Lancet"},{"key":"1459_CR4","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","volume":"42","author":"Wilson","year":"1999","unstructured":"Wilson WA, Gharavi AE, Koike T et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309\u20131311","journal-title":"Arthritis Rheum"},{"key":"1459_CR5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295\u2013306","journal-title":"J Thromb Haemost"},{"key":"1459_CR6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-0033-1364185","volume":"40","author":"Moore","year":"2014","unstructured":"Moore GW (2014) Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 40(2):163\u2013171","journal-title":"Semin Thromb Hemost"},{"key":"1459_CR7","first-page":"1589","volume":"22","author":"Mujic","year":"1995","unstructured":"Mujic F, Cuadrado MJ, Lloyd M et al (1995) Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. J Rheumatol 22(8):1589\u20131592","journal-title":"J Rheumatol"},{"key":"1459_CR8","unstructured":"Specker CH (2002) Das Antiphospholipidsyndrom. Shaker, Aachen"},{"key":"1459_CR9","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(10)60709-X","volume":"376","author":"Ruiz-Irastorza","year":"2010","unstructured":"Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA (2010) Antiphospholipid syndrome. Lancet 376(9751):1498\u20131509","journal-title":"Lancet"},{"key":"1459_CR10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0002-9343(94)90108-2","volume":"96","author":"Vianna","year":"1994","unstructured":"Vianna JL, Khamashta MA, Ordi-Ros J et al (1994) Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 96:3\u20139","journal-title":"Am J Med"},{"key":"1459_CR11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/096120339600500507","volume":"5","author":"Harris","year":"1996","unstructured":"Harris EN, Pierangeli SS (1996) Functional effects of anticardiolipin antibodies. Lupus 5:372\u2013377","journal-title":"Lupus"},{"key":"1459_CR12","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jama.295.9.1050","volume":"295","author":"Lim","year":"2006","unstructured":"Lim W, Crowther MA, Eikelboom JW (2006) Management of antiphospholipid antibody syndrome. A systematic review. JAMA 295:1050\u20131057","journal-title":"JAMA"},{"key":"1459_CR13","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/rheumatology\/37.11.1229","volume":"37","author":"Bertolaccini","year":"1998","unstructured":"Bertolaccini ML, Roch B, Amengual O et al (1998) Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome. Br J Rheumatol 37:1229\u20131232","journal-title":"Br J Rheumatol"},{"key":"1459_CR14","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1177\/096120339800700202","volume":"7","author":"Sheng","year":"1998","unstructured":"Sheng Y, Kandiah DA, Krilis SA (1998) Beta2-glycoprotein I: target antigen for \u201aantiphospholipid\u2018 antibodies. Immunological and molecular aspects. Lupus 7(Suppl 2):S5\u2013S9","journal-title":"Lupus"},{"key":"1459_CR15","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2141.1995.tb05324.x","volume":"91","author":"McNally","year":"1995","unstructured":"McNally T et al (1995) The use of anti-\u03b22-glycoprotein I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk for thrombosis. Br J Haematol 91:471\u2013473","journal-title":"Br J Haematol"},{"key":"1459_CR16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1055\/s-0037-1613606","volume":"90","author":"Neville","year":"2003","unstructured":"Neville C, Rauch J, Kassis J et al (2003) Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb Haemost 90(1):108\u2013115","journal-title":"Thromb Haemost"},{"key":"1459_CR17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF02207667","volume":"10","author":"Meroni","year":"1991","unstructured":"Meroni PL, Rivolta R, Ghidoni P (1991) Histopathological findings in cases of systemic lupus erythematosus-associated antiphospholipid syndrome. Clin Rheumatol 10:211\u2013214","journal-title":"Clin Rheumatol"},{"key":"1459_CR18","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/0046-8177(95)90218-X","volume":"26","author":"Hughson","year":"1995","unstructured":"Hughson MD, McCarty GA, Brumback RA (1995) Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome. Hum Pathol 26:716\u2013724","journal-title":"Hum Pathol"},{"key":"1459_CR19","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1177\/0961203314540764","volume":"23","author":"Cervera","year":"2014","unstructured":"Cervera R, Rodr\u00edguez-Pint\u00f3 I, G Espinosa on behalf of the Task Force on Catastrophic Antiphospholipid Syndrome (2014) Catastrophic antiphospholipid syndrome: task force report summary. Lupus 23(12):1283\u20131285","journal-title":"Lupus"},{"key":"1459_CR20","doi-asserted-by":"crossref","unstructured":"Erkan D, Yazici Y, Peterson MG et al (2002) A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 41(8):924\u2013929","DOI":"10.1093\/rheumatology\/41.8.924"},{"key":"1459_CR21","first-page":"1560","volume":"31","author":"Giron-Gonzalez","year":"2004","unstructured":"Giron-Gonzalez JA, Garcia del Rio E, Rodriguez C et al (2004) Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 31(8):1560\u20131567","journal-title":"J Rheumatol"},{"key":"1459_CR22","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1177\/096120339800700216","volume":"7","author":"Brey","year":"1998","unstructured":"Brey RL, Escalante A (1998) Neurological manifestations of antiphospholipid antibody syndrome. Lupus 7(Suppl 2):S67\u2013S74","journal-title":"Lupus"},{"key":"1459_CR23","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","volume":"46","author":"Cervera","year":"2002","unstructured":"Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46(4):1019\u20131027","journal-title":"Arthritis Rheum"},{"key":"1459_CR24","unstructured":"Erkan D, Bermas BL, Schur PH (2014) Clinical manifestations of the antiphospholipid syndrome. In: Pisetsky DS (ed) UpToDate. UpToDate, Waltham"},{"key":"1459_CR25","first-page":"CD002859","volume":"2","author":"Empson","year":"2005","unstructured":"Empson M, Lassere M, Craig J, Scott J (2005) Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2:CD002859","journal-title":"Cochrane Database Syst Rev"},{"key":"1459_CR26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1055\/s-2003-40444","volume":"28","author":"Fischer-Betz","year":"2003","unstructured":"Fischer-Betz R, Specker C (2003) Antiphospholipid-Antik\u00f6rper und Schwangerschaft. Akt Rheumatol 28(3):131\u2013137","journal-title":"Akt Rheumatol"},{"key":"1459_CR27","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(98)10266-0","volume":"353","author":"Rosendaal","year":"1999","unstructured":"Rosendaal FR (1999) Venous thrombosis: a multicausal disease. Lancet 353:1167\u20131173","journal-title":"Lancet"},{"key":"1459_CR28","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0b013e3182009701","volume":"123","author":"Roger","year":"2011","unstructured":"Roger VL, Go AS, Lloyd-Jones DM et al (2011) Heart disease and stroke statistics: 2011 update. A report from the American Heart Association. Circulation 123(4):e18\u2013e209","journal-title":"Circulation"},{"key":"1459_CR29","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/ard.2010.142042","volume":"70","author":"Ruffatti","year":"2011","unstructured":"Ruffatti A, Del Ross T, Ciprian M et al (2011) Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 70(6):1083\u20131086","journal-title":"Ann Rheum Dis"},{"key":"1459_CR30","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","volume":"118","author":"Pengo","year":"2011","unstructured":"Pengo V, Ruffatti A, Legnani C et al (2011) Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 118(17):4714\u20134718","journal-title":"Blood"},{"key":"1459_CR31","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1002\/art.21224","volume":"52","author":"Mok","year":"2005","unstructured":"Mok CC, Tang SSK, To CH et al (2005) Incidence and risk factors of thromboembolism systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 52(9):2774\u20132782","journal-title":"Arthritis Rheum"},{"key":"1459_CR32","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1161\/01.STR.28.9.1660","volume":"28","author":"Levine","year":"1997","unstructured":"Levine SR, Salowich-Palm L, Sawaya KL et al (1997) IgG anticardiolipin antibody titer\u2009 >\u200940 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 28(9):1660\u20131665","journal-title":"Stroke"},{"key":"1459_CR33","unstructured":"Bermas BL, Schur PH, Kaplan AA (2014) Treatment of the antiphospholipid syndrome. In: Pisetsky DS (ed) UpToDate. UpToDate, Waltham"},{"key":"1459_CR34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/0961203310395803","volume":"20","author":"Ruiz-Irastorza","year":"2011","unstructured":"Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I et al (2011) Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on Antiphospholipid Antibodies. Lupus 20(2):206\u2013218","journal-title":"Lupus"},{"key":"1459_CR35","doi-asserted-by":"crossref","unstructured":"Erkan D, Patel S, Nuzzo M et al (2008) Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers. Rheumatology (Oxford) 47(Suppl 3):iii23\u201327","DOI":"10.1093\/rheumatology\/ken181"},{"key":"1459_CR36","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1590\/S0482-50042013000200005","volume":"53","author":"Danowski","year":"2013","unstructured":"Danowski A, Rego J, Kakehasi AM et al (2013) Guidelines for the treatment of antiphospholipid syndrome. Rev Bras Reumatol 53(2):184\u2013192","journal-title":"Rev Bras Reumatol"},{"key":"1459_CR37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1055\/s-0030-1248295","volume":"35","author":"Schr\u00f6der","year":"2011","unstructured":"Schr\u00f6der JO, Zeuner RA, Specker C (2011) Systemischer Lupus erythematodes und Antiphospholipid-Syndrom. Akt Rheumatol 35(1):24\u201332","journal-title":"Akt Rheumatol"},{"key":"1459_CR38","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.autrev.2014.01.053","volume":"13","author":"Erkan","year":"2014","unstructured":"Erkan D, Aguiar CL, Andrade D et al (2014) 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 13(6):685\u2013996","journal-title":"Autoimmun Rev"},{"key":"1459_CR39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00393-006-0127-3","volume":"66","author":"Specker","year":"2007","unstructured":"Specker C (2007) Antiphospholipidsyndrom. Z Rheumatol 66:41\u201353","journal-title":"Z Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-014-1459-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-014-1459-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-014-1459-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T23:14:18Z","timestamp":1566515658000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-014-1459-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["1459"],"URL":"https:\/\/doi.org\/10.1007\/s00393-014-1459-z","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}